Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.

Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study. Allergy Sindher, S. B., Nadeau, K. C., Chinthrajah, R. S., Leflein, J. G., Bégin, P., Ohayon, J. A., Ponda, P., Wambre, E., Liu, J., Khokhar, F. A., Akinlade, B., Maloney, J., Orengo, J. M., Hamilton, J. D., Kamal, M. A., Hooper, A. T., Patel, N., Patel, K., Laws, E., Mannent, L. P., Radin, A. R. 2024

Abstract

Peanut allergy is a potentially life-threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)-4/IL-13, improved safety and desensitization to peanut exposure in children with peanut allergy.A Phase II, 24-week, multicenter, single-arm, open-label, proof-of-concept study was conducted in the USA and Canada (NCT03793608). Children/adolescents with peanut allergy received subcutaneous dupilumab 300?mg (=?60?kg) or 200?mg (=?20 to

View details for DOI 10.1111/all.16404

View details for PubMedID 39673452